Serveur d'exploration sur les peptides biopesticides

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Restore the brake on tumor progression.

Identifieur interne : 000B80 ( Main/Exploration ); précédent : 000B79; suivant : 000B81

Restore the brake on tumor progression.

Auteurs : Renata E. Gordon [États-Unis] ; Li Zhang [République populaire de Chine] ; Zeng-Jie Yang [République populaire de Chine]

Source :

RBID : pubmed:28389227

Descripteurs français

English descriptors

Abstract

Sonic hedgehog (Shh) signaling plays a key role in regulation of normal development. The negative feedback mechanism mediated by the transcriptional factor, Gli3, acts to finely tune Shh signaling, providing tight control of normal developmental processes. Hyperactivation of Shh signaling often leads to many human malignancies, including basal cell carcinoma and medulloblastoma (MB). However, how tumor cells sustain the aberrant activation of Shh signaling is still not completely understood. We recently revealed that during MB formation, tumor cells express Nestin, a type VI intermediate filament protein, which maintains uncontrolled Shh signaling by abolishing negative feedback by Gli3. Therefore, Nestin expression is a necessary step for MB formation. These findings highlight the novel function of Nestin in regulating Shh signaling, as well as the important role of a disrupted negative feedback mechanism in MB tumorigenesis. Further, restoration of the intrinsic negative feedback by repressing Nestin expression represents a promising approach to treat MB as well as other Shh signaling associated malignancies.

DOI: 10.1016/j.bcp.2017.04.003
PubMed: 28389227
PubMed Central: PMC5496785


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Restore the brake on tumor progression.</title>
<author>
<name sortKey="Gordon, Renata E" sort="Gordon, Renata E" uniqKey="Gordon R" first="Renata E" last="Gordon">Renata E. Gordon</name>
<affiliation wicri:level="2">
<nlm:affiliation>Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA 19111, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA 19111</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name>
<affiliation wicri:level="1">
<nlm:affiliation>Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021</wicri:regionArea>
<wicri:noRegion>Jiangsu 215021</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Yang, Zeng Jie" sort="Yang, Zeng Jie" uniqKey="Yang Z" first="Zeng-Jie" last="Yang">Zeng-Jie Yang</name>
<affiliation wicri:level="1">
<nlm:affiliation>Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA 19111, USA; Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, China. Electronic address: zengjie.yang@fccc.edu.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA 19111, USA; Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021</wicri:regionArea>
<wicri:noRegion>Jiangsu 215021</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28389227</idno>
<idno type="pmid">28389227</idno>
<idno type="doi">10.1016/j.bcp.2017.04.003</idno>
<idno type="pmc">PMC5496785</idno>
<idno type="wicri:Area/Main/Corpus">000D18</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000D18</idno>
<idno type="wicri:Area/Main/Curation">000D18</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000D18</idno>
<idno type="wicri:Area/Main/Exploration">000D18</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Restore the brake on tumor progression.</title>
<author>
<name sortKey="Gordon, Renata E" sort="Gordon, Renata E" uniqKey="Gordon R" first="Renata E" last="Gordon">Renata E. Gordon</name>
<affiliation wicri:level="2">
<nlm:affiliation>Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA 19111, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA 19111</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name>
<affiliation wicri:level="1">
<nlm:affiliation>Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021</wicri:regionArea>
<wicri:noRegion>Jiangsu 215021</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Yang, Zeng Jie" sort="Yang, Zeng Jie" uniqKey="Yang Z" first="Zeng-Jie" last="Yang">Zeng-Jie Yang</name>
<affiliation wicri:level="1">
<nlm:affiliation>Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA 19111, USA; Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, China. Electronic address: zengjie.yang@fccc.edu.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA 19111, USA; Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021</wicri:regionArea>
<wicri:noRegion>Jiangsu 215021</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Biochemical pharmacology</title>
<idno type="eISSN">1873-2968</idno>
<imprint>
<date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals (MeSH)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Cerebellar Neoplasms (drug therapy)</term>
<term>Cerebellar Neoplasms (metabolism)</term>
<term>Cerebellar Neoplasms (pathology)</term>
<term>Cerebellar Neoplasms (physiopathology)</term>
<term>Disease Progression (MeSH)</term>
<term>Feedback, Physiological (drug effects)</term>
<term>Hedgehog Proteins (metabolism)</term>
<term>Humans (MeSH)</term>
<term>Kruppel-Like Transcription Factors (metabolism)</term>
<term>Medulloblastoma (drug therapy)</term>
<term>Medulloblastoma (metabolism)</term>
<term>Medulloblastoma (pathology)</term>
<term>Medulloblastoma (physiopathology)</term>
<term>Models, Biological (MeSH)</term>
<term>Molecular Targeted Therapy (MeSH)</term>
<term>Neoplasm Proteins (antagonists & inhibitors)</term>
<term>Neoplasm Proteins (metabolism)</term>
<term>Nerve Tissue Proteins (antagonists & inhibitors)</term>
<term>Nerve Tissue Proteins (metabolism)</term>
<term>Nestin (antagonists & inhibitors)</term>
<term>Nestin (metabolism)</term>
<term>Signal Transduction (drug effects)</term>
<term>Tumor Burden (MeSH)</term>
<term>Zinc Finger Protein Gli3 (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux (MeSH)</term>
<term>Antinéoplasiques (usage thérapeutique)</term>
<term>Charge tumorale (MeSH)</term>
<term>Facteurs de transcription Krüppel-like (métabolisme)</term>
<term>Humains (MeSH)</term>
<term>Modèles biologiques (MeSH)</term>
<term>Médulloblastome (anatomopathologie)</term>
<term>Médulloblastome (métabolisme)</term>
<term>Médulloblastome (physiopathologie)</term>
<term>Médulloblastome (traitement médicamenteux)</term>
<term>Nestine (antagonistes et inhibiteurs)</term>
<term>Nestine (métabolisme)</term>
<term>Protéine à doigts de zinc Gli3 (MeSH)</term>
<term>Protéines Hedgehog (métabolisme)</term>
<term>Protéines de tissu nerveux (antagonistes et inhibiteurs)</term>
<term>Protéines de tissu nerveux (métabolisme)</term>
<term>Protéines tumorales (antagonistes et inhibiteurs)</term>
<term>Protéines tumorales (métabolisme)</term>
<term>Rétrocontrôle physiologique (effets des médicaments et des substances chimiques)</term>
<term>Thérapie moléculaire ciblée (MeSH)</term>
<term>Transduction du signal (effets des médicaments et des substances chimiques)</term>
<term>Tumeurs du cervelet (anatomopathologie)</term>
<term>Tumeurs du cervelet (métabolisme)</term>
<term>Tumeurs du cervelet (physiopathologie)</term>
<term>Tumeurs du cervelet (traitement médicamenteux)</term>
<term>Évolution de la maladie (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>Neoplasm Proteins</term>
<term>Nerve Tissue Proteins</term>
<term>Nestin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Hedgehog Proteins</term>
<term>Kruppel-Like Transcription Factors</term>
<term>Neoplasm Proteins</term>
<term>Nerve Tissue Proteins</term>
<term>Nestin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antineoplastic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Médulloblastome</term>
<term>Tumeurs du cervelet</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>Nestine</term>
<term>Protéines de tissu nerveux</term>
<term>Protéines tumorales</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Feedback, Physiological</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Cerebellar Neoplasms</term>
<term>Medulloblastoma</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Rétrocontrôle physiologique</term>
<term>Transduction du signal</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Cerebellar Neoplasms</term>
<term>Medulloblastoma</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Facteurs de transcription Krüppel-like</term>
<term>Médulloblastome</term>
<term>Nestine</term>
<term>Protéines Hedgehog</term>
<term>Protéines de tissu nerveux</term>
<term>Protéines tumorales</term>
<term>Tumeurs du cervelet</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Cerebellar Neoplasms</term>
<term>Medulloblastoma</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr">
<term>Médulloblastome</term>
<term>Tumeurs du cervelet</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Cerebellar Neoplasms</term>
<term>Medulloblastoma</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Médulloblastome</term>
<term>Tumeurs du cervelet</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Antinéoplasiques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Disease Progression</term>
<term>Humans</term>
<term>Models, Biological</term>
<term>Molecular Targeted Therapy</term>
<term>Tumor Burden</term>
<term>Zinc Finger Protein Gli3</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Charge tumorale</term>
<term>Humains</term>
<term>Modèles biologiques</term>
<term>Protéine à doigts de zinc Gli3</term>
<term>Thérapie moléculaire ciblée</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Sonic hedgehog (Shh) signaling plays a key role in regulation of normal development. The negative feedback mechanism mediated by the transcriptional factor, Gli3, acts to finely tune Shh signaling, providing tight control of normal developmental processes. Hyperactivation of Shh signaling often leads to many human malignancies, including basal cell carcinoma and medulloblastoma (MB). However, how tumor cells sustain the aberrant activation of Shh signaling is still not completely understood. We recently revealed that during MB formation, tumor cells express Nestin, a type VI intermediate filament protein, which maintains uncontrolled Shh signaling by abolishing negative feedback by Gli3. Therefore, Nestin expression is a necessary step for MB formation. These findings highlight the novel function of Nestin in regulating Shh signaling, as well as the important role of a disrupted negative feedback mechanism in MB tumorigenesis. Further, restoration of the intrinsic negative feedback by repressing Nestin expression represents a promising approach to treat MB as well as other Shh signaling associated malignancies.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">28389227</PMID>
<DateCompleted>
<Year>2017</Year>
<Month>07</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-2968</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>138</Volume>
<PubDate>
<Year>2017</Year>
<Month>08</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical pharmacology</Title>
<ISOAbbreviation>Biochem Pharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Restore the brake on tumor progression.</ArticleTitle>
<Pagination>
<MedlinePgn>1-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0006-2952(17)30192-2</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bcp.2017.04.003</ELocationID>
<Abstract>
<AbstractText>Sonic hedgehog (Shh) signaling plays a key role in regulation of normal development. The negative feedback mechanism mediated by the transcriptional factor, Gli3, acts to finely tune Shh signaling, providing tight control of normal developmental processes. Hyperactivation of Shh signaling often leads to many human malignancies, including basal cell carcinoma and medulloblastoma (MB). However, how tumor cells sustain the aberrant activation of Shh signaling is still not completely understood. We recently revealed that during MB formation, tumor cells express Nestin, a type VI intermediate filament protein, which maintains uncontrolled Shh signaling by abolishing negative feedback by Gli3. Therefore, Nestin expression is a necessary step for MB formation. These findings highlight the novel function of Nestin in regulating Shh signaling, as well as the important role of a disrupted negative feedback mechanism in MB tumorigenesis. Further, restoration of the intrinsic negative feedback by repressing Nestin expression represents a promising approach to treat MB as well as other Shh signaling associated malignancies.</AbstractText>
<CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gordon</LastName>
<ForeName>Renata E</ForeName>
<Initials>RE</Initials>
<AffiliationInfo>
<Affiliation>Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA 19111, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Zeng-Jie</ForeName>
<Initials>ZJ</Initials>
<AffiliationInfo>
<Affiliation>Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA 19111, USA; Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, China. Electronic address: zengjie.yang@fccc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA178380</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 CA185504</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U50 DP424071</GrantID>
<Acronym>DP</Acronym>
<Agency>NCCDPHP CDC HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2017</Year>
<Month>04</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Biochem Pharmacol</MedlineTA>
<NlmUniqueID>0101032</NlmUniqueID>
<ISSNLinking>0006-2952</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C065683">GLI3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051741">Kruppel-Like Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C577484">NES protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064231">Nestin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C509239">SHH protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000074290">Zinc Finger Protein Gli3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002528" MajorTopicYN="N">Cerebellar Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D025461" MajorTopicYN="N">Feedback, Physiological</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D053823" MajorTopicYN="N">Hedgehog Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051741" MajorTopicYN="N">Kruppel-Like Transcription Factors</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008527" MajorTopicYN="N">Medulloblastoma</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D064231" MajorTopicYN="N">Nestin</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000074290" MajorTopicYN="N">Zinc Finger Protein Gli3</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="Y">Medulloblastoma</Keyword>
<Keyword MajorTopicYN="Y">Negative feedback loop</Keyword>
<Keyword MajorTopicYN="Y">Nestin</Keyword>
<Keyword MajorTopicYN="Y">Sonic hedgehog</Keyword>
<Keyword MajorTopicYN="Y">Therapeutic target</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2017</Year>
<Month>01</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2017</Year>
<Month>04</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2017</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>7</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2017</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">28389227</ArticleId>
<ArticleId IdType="pii">S0006-2952(17)30192-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.bcp.2017.04.003</ArticleId>
<ArticleId IdType="pmc">PMC5496785</ArticleId>
<ArticleId IdType="mid">NIHMS871520</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Nat Rev Cancer. 2002 May;2(5):361-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12044012</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Sci. 1998 Jul 30;111 ( Pt 14):1951-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9645943</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Neurosci. 1998 Sep;21(9):375-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9735945</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2007 Apr 13;282(15):10846-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17283082</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2008 Mar;13(3):249-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18328428</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13291-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15331785</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Acta Neuropathol. 2011 Mar;121(3):381-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21267586</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9958-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12904579</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Mol Life Sci. 2004 Oct;61(19-20):2510-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15526158</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1999 Apr 2;274(14):9881-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10092680</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Am Soc Nephrol. 2006 May;17(5):1283-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16571784</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer Res. 2013 Jul;11(7):768-79</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23552743</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Neurosci. 1998 Sep;21(9):370-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9735944</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2012 Sep 15;18(18):4883-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22718857</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2013 Nov 15;19(22):6305-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24077351</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Mol Life Sci. 2016 Dec;73(23 ):4397-4413</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">27342992</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Cancer. 2011 May 26;11(7):493-501</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21614026</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Brain Tumor Pathol. 2012 Jul;29(3):160-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22350668</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Neurosci. 2013 Dec;16(12 ):1737-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24141309</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Neurosci. 1997 Mar;9(3):452-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9104587</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2010 Aug 12;466(7308):829-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20703299</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neoplasma. 2010;57(4):291-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20429619</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2011 Mar 4;144(5):646-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21376230</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Invest Dermatol. 2009 Nov;129(11):2711-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19554024</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>World J Gastroenterol. 2013 Jan 7;19(1):42-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23326161</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2011 Aug 1;71(15):5057-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21771911</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Brain Res. 1997 Sep 12;768(1-2):1-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9369294</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2009 Sep 17;361(12 ):1173-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19726761</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Pathol. 2010 May;41(5):737-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20132963</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neurosci Behav Physiol. 2008 Feb;38(2):165-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18197384</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancers (Basel). 2016 Feb 15;8(2):null</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26891329</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1999 Aug 20;274(34):23996-4006</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10446168</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurosci. 1985 Dec;5(12):3310-28</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">4078630</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Sci. 1992 Oct;103 ( Pt 2):589-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1478958</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Annu Rev Cell Dev Biol. 2011;27:513-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21801010</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2016 Sep 15;76(18):5573-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">27496710</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Di Yi Jun Yi Da Xue Xue Bao. 2004 Feb;24(2):207-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14965830</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5924-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17062662</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Exp Cell Res. 1999 May 1;248(2):509-19</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10222142</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Sci. 2015 Jul;106(7):803-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25940879</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lab Invest. 2004 Dec;84(12):1581-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15502861</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Stem Cells. 2010 Dec;28(12):2162-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20963821</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Neurol. 2007 Dec;6(12):1073-85</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18031705</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biotech Histochem. 2015 Jul;90(5):384-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25839093</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2011 Apr 10;29(11):1408-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20823417</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 2006 Oct 18;25(20):4808-19</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17036052</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2004 Jul 2;279(27):27994-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15117961</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2008 Aug 12;14 (2):135-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18691548</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2009 Oct 23;326(5952):572-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19726788</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>F1000 Biol Rep. 2011;3:5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21655335</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neuropathol Exp Neurol. 2001 Jun;60(6):588-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11398835</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Histol Histopathol. 2005 Apr;20(2):665-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15736068</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer Ther. 2005 Oct;4(10):1533-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16227402</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bioessays. 1994 Jul;16(7):489-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7945277</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 1990 Feb 23;60(4):585-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1689217</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Histochem Cell Biol. 2006 Dec;126(6):723-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16835754</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Mol Cell Biol. 2007 Jul;8(7):562-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17551517</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Dev Biol. 1994 Sep;165(1):216-28</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8088440</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2016 Oct 1;197(7):2686-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">27574301</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neuron. 1994 Jan;12(1):11-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8292356</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 2004 Oct;24(20):8834-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15456859</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>République populaire de Chine</li>
<li>États-Unis</li>
</country>
<region>
<li>Pennsylvanie</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="Pennsylvanie">
<name sortKey="Gordon, Renata E" sort="Gordon, Renata E" uniqKey="Gordon R" first="Renata E" last="Gordon">Renata E. Gordon</name>
</region>
</country>
<country name="République populaire de Chine">
<noRegion>
<name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name>
</noRegion>
<name sortKey="Yang, Zeng Jie" sort="Yang, Zeng Jie" uniqKey="Yang Z" first="Zeng-Jie" last="Yang">Zeng-Jie Yang</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B80 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B80 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    BiopestPeptidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:28389227
   |texte=   Restore the brake on tumor progression.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28389227" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a BiopestPeptidV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 19:22:35 2020. Site generation: Thu Nov 19 19:33:26 2020